**STANDFIRST**

Variation in macrophage phagocytosis across diverse GBS isolates

Group B *Streptococcus* (GBS) is a β-hemolytic, encapsulated, Gram-positive bacterium with a propensity to cause infections in adults with chronic medical conditions, pregnant women, and neonates \[[@B1], [@B2]\]. GBS causes a range of illnesses, from asymptomatic colonization to invasive disease. The basis of this clinical variability is unclear, though differences across GBS strains clearly matter, as certain capsular serotypes and genetic subtypes are more common causes of invasive disease than others \[[@B3]\]. Of the 10 known capsular serotypes, five cause the vast majority of invasive infections \[[@B3]\]. A variety of bacterial virulence factors influences the risk for, and severity of, infections \[[@B4]\]. The presence (and/or expression) of such factors can vary widely across distinct GBS strains, and this likely explains many differences in colonization, immune evasion, and tissue invasion \[[@B4]\]. On the other hand, host determinants of vulnerability to infection remain incompletely defined, though the presence of anti-capsular antibodies clearly influences risk and provides the rationale for developing anti-capsular vaccines \[[@B5]\]. Anti-capsular immunoglobulins generated by previously exposed (or immunized) hosts can augment the function of innate phagocytes such as tissue macrophages. However, in non-immune persons with low levels of preexisting antibodies, macrophages (and other phagocytes) must internalize bacteria that are either opsonized by non-specific complement proteins or unopsonized bacteria. Because the sialylated polysaccharide capsule of GBS prevents host complement deposition on the bacterial surface \[[@B6]\], the capacity for macrophages to internalize unopsonized GBS bacteria is likely important. It is possible that diversity in the ability of GBS strains to cause disease reflects differences in macrophage evasion. We hypothesized that the capacity for macrophages to phagocytose unopsonized GBS would vary across distinct clinical strains, and such differences would reflect serotype diversity, possibly helping to explain why GBS demonstrates such distinct serotype diversity in its propensity to cause infection.

To test this hypothesis we utilized a high-throughput assay of bacterial phagocytosis using the human monocyte-like THP-1 cell line (ATCC TIB-202), differentiated into a macrophage-like cells with phorbol 12-myristate 13-acetate (PMA) \[[@B7], [@B8]\] as we have described for *S. pyogenes* \[[@B9], [@B10]\]. A diverse collection of 35 clinical GBS isolates ([Table 1](#T1){ref-type="table"}) was heat-inactivated, washed, resuspended, and labeled with the fluorescent dye fluorescein isothiocyanate (FITC) for use in the phagocytosis assay. In addition to facilitating assay standardization, bacterial heat inactivation limited the likelihood that newly synthesized or secreted mediators would influence macrophage behavior. All invasive GBS strains were originally recovered from neonatal blood or cerebral spinal fluid \[[@B11]\], while the colonizing strains were recovered via vaginal/rectal swabs from women during and after pregnancy \[[@B12]\]. Bacteria were incubated with PMA-differentiated THP-1 cells for three hours (at a ratio of 150 bacteria per cell) prior to measuring intracellular fluorescence as described \[[@B9], [@B10], [@B13]\]. Growth curves for each bacterial isolate obtained in tandem with heat-inactivation and fluorescent labeling allowed the generation of standard curves to estimate the number of fluorescently labeled bacteria internalized on a per-macrophage basis ([Figure 1](#F1){ref-type="fig"}).

###### 

Molecular characteristics and source of strains evaluated in this study.

  Strain ID   Strain Type   Sequence Type (ST)   Pilus Island Profile (PI)   Molecular Serotype   Clinical Presentation
  ----------- ------------- -------------------- --------------------------- -------------------- -----------------------------
  GB00112     Colonizing    ST-17                PI-2b                       cpsIII               Vaginal/rectal colonization
  GB00557     Colonizing    ST-17                PI-2b                       cpsIII               Vaginal/rectal colonization
  GB00663     Colonizing    ST-19                PI-2a                       cpsIII               Vaginal/rectal colonization
  GB00590     Colonizing    ST-19                Unknown                     cpsIII               Vaginal/rectal colonization
  GB00012     Colonizing    ST-1                 Unknown                     cpsV                 Vaginal/rectal colonization
  GB00571     Colonizing    ST-19                PI-2a                       cpsIII               Vaginal/rectal colonization
  GB00653     Colonizing    ST-12                Unknown                     cpsII                Vaginal/rectal colonization
  GB00020     Colonizing    ST-1                 Unknown                     cpsV                 Vaginal/rectal colonization
  GB00084     Colonizing    ST-1                 PI-2b                       cpsVIII              Vaginal/rectal colonization
  GB00555     Colonizing    ST-12                Unknown                     cpsIb                Vaginal/rectal colonization
  GB00279     Colonizing    ST-23                Unknown                     cpsII                Vaginal/rectal colonization
  GB00097     Colonizing    ST-17                PI-2b                       cpsIII               Vaginal/rectal colonization
  GB00291     Colonizing    ST-12                Unknown                     cpsII                Vaginal/rectal colonization
  GB00285     Colonizing    ST-12                Unknown                     cpsIb                Vaginal/rectal colonization
  GB00651     Colonizing    ST-19                PI-2a                       cpsIb                Vaginal/rectal colonization
  GB00561     Colonizing    ST-19                PI-2a                       cpsV                 Vaginal/rectal colonization
  NEM316      Invasive      ST-23                PI-2a                       cpsIII               EOD/sepsis
  GB00079     Invasive      ST-19                PI-2a                       cpsIII               EOD/sepsis
  GB00418     Invasive      ST-17                PI-2b                       cpsIII               EOD/sepsis
  GB01455     Invasive      ST-12                Unknown                     cpsII                Stillbirth
  GB00411     Invasive      ST-17                PI-2b                       cpsIII               EOD/sepsis
  GB00377     Invasive      ST-19                PI-2a                       cpsIII               EOD/sepsis
  GB00037     Invasive      ST-1                 Unknown                     cpsV                 EOD/sepsis
  GB00033     Invasive      ST-23                PI-2a                       cpsIa                EOD/sepsis
  GB00036     Invasive      ST-19                PI-2a                       cpsIII               EOD/sepsis
  GB00310     Invasive      ST-1                 PI-2a                       cpsV                 EOD/sepsis
  GB00686     Invasive      ST-1                 Unknown                     cpsV                 Stillbirth
  GB00910     Invasive      ST-12                Unknown                     cpsII                EOD/sepsis
  GB01007     Invasive      ST-19                PI-2a                       cpsIII               Stillbirth
  GB00390     Invasive      ST-23                Unknown                     cpsIa                EOD/sepsis/meningitis
  GB00374     Invasive      ST-12                Unknown                     cpsIb                EOD/sepsis
  GB00438     Invasive      ST-12                Unknown                     cpsIb                LOD/sepsis
  GB01454     Invasive      ST-1                 Unknown                     cpsV                 Stillbirth
  GB00045     Invasive      ST-17                PI-2b                       cpsIII               EOD/sepsis
  GB00066     Invasive      ST-19                PI-2a                       cpsIII               EOD/sepsis

EOD = early onset disease; LOD = late onset disease

**Table 1: Clinical characteristics of group B streptococcus (*S. agalactiae*) isolates.** Strain ID, clinical type, sequence type (ST), pilus island (PI) profile, molecular serotype, and clinical presentation data on 35 clinical isolates screened in our phagocytosis assay.

![**Phagocytosis of clinical group B streptococcal isolates by human macrophages**. (A) THP-1 cells were assessed in their ability to phagocytose 35 diverse clinical strains of GBS. Cells were challenged with heat killed, FITC-labeled GBS at a MOI of 150:1. Phagocytosis of GBS was quantified by fluorometry after 3 hr. Data are represented as mean ± standard error of the mean (SEM); n = 3-5 for each. \**P* \< 0.05 and \*\**P* \< 0.01 by 1-way ANOVA and Tukey\'s post-test compared with phagocytosis of the GB590 strain. GBS is stratified by (B) molecular serotype (capsule type), (C) sequence type, (D) clinical presentation, or (E) pilus type. Phagocytosis of GB37 and GB590 was confirmed in (F) human primary placental macrophages, (G) human peripheral blood monocytes, and (H) new independent experiments using THP-1 cells and just these two strains. Data are represented as mean ± SEM of at least three independent experiments. \**P* \< 0.05 by paired student t-test (two-tailed).](pai-3-063-g001){#F1}

As illustrated ([Figure 1](#F1){ref-type="fig"}A), we measured a wide range of bacterial phagocytosis by the number of THP-1 cells, ranging from 1.133 ± 0.584 bacteria/cell (± standard error of the mean) to 6.533 ± 0.935 bacteria per cell. These differences were significant by ANOVA, with significance observed specifically between the most-highly internalized strain (GB590) compared to 10 of the least-phagocytosed isolates ([Figure 1](#F1){ref-type="fig"}A). These data support the first part of our hypothesis. Interestingly, however, when stratified by capsular serotype ([Figure 1](#F1){ref-type="fig"}B), multilocus sequence type ([Figure 1](#F1){ref-type="fig"}C as described in \[[@B14]\]), or strain source ([Figure 1](#F1){ref-type="fig"}D), no significant differences were observed. For the subset of strains of GBS for which we had information related to the presence or absence of the gene encoding the pilus backbone protein Spb1 (SAN1518, PI-2b) \[[@B15]\], this feature did not associate with differences in macrophage uptake ([Figure 1](#F1){ref-type="fig"}E). In summary, the data fail to support the second part of our hypothesis and suggest that variables other than capsular serotype, genetic sequence type, pilus type, or clinical source of the GBS strains explain the diverse capacity for THP-1 cells to internalize the bacteria. Future studies might evaluate whether these bacterial characteristics have more of an influence on macrophage phagocytosis mediated by opsonins, such as complement or immunoglobulin.

Because large screening studies are susceptible to false discovery (type I error), we sought to validate findings from the broad screen ([Figure 1](#F1){ref-type="fig"}A) by comparing a single highly phagocytosed GBS strain to a single poorly internalized GBS strain head-to-head. The same fluorescence assay was utilized, but we conducted experiments in either PMA-differentiated THP-1 cells or two types of primary human phagocytes ([Figures 1](#F1){ref-type="fig"}F-H). We used GBS strain GB590 because it was the most highly internalized bacterium in our screen, and strain GB37, a poorly internalized isolate. GB37 is notable because we have previously characterized it as a highly virulent strain *in vivo* and have sequenced the genome \[[@B16], [@B17]\]. Interestingly, GB37 was also found to be more virulent in systemic infection models in mice than GB590 \[[@B18]\], although the relation of *in vivo* behavior to our current *in vitro* findings is not clear. As shown in [Figure 1](#F1){ref-type="fig"}F, the difference in phagocytosis observed in our initial broad screen was confirmed in human, primary placental macrophages, obtained from term, non-laboring placentas obtained at the time of Cesarean section, as previously described \[[@B10], [@B19]\]. This significant difference in phagocytosis was also observed in human primary blood monocytes (isolated as we have described \[[@B20]\]; [Figure 1](#F1){ref-type="fig"}G) and repeated again in PMA-differentiated THP-1 cells ([Figure 1](#F1){ref-type="fig"}H).

This study demonstrates that human macrophage-like cells (PMA-differentiated THP-1 cells) and primary human phagocytes phagocytose diverse GBS strains differentially. The basis of this does not appear to reflect capsular serotype, genomic sequence type, or the association of the GBS isolates with invasive disease. Future studies are needed to define the bacterial determinants of this variability, including the possibility that differences in sialic acid modifications of the GBS capsule might explain the varied macrophage responses, through interactions with host cell siglec receptors (reviewed in \[[@B21]\]). Interestingly, a previous study of 163 GBS isolates from different phylo-genetic backgrounds assessed non-opsonic phagocytosis assays using the mouse J774A.1 macrophage-like cell line \[[@B22]\]. As in our present study, they noticed a wide range of phagocytic activity across strains. However, their results demonstrated a relationship between phagocytosis and the presence of the gene encoding the pilus backbone protein, Spb1, with Spb1 expression by GBS being associated with greater phagocytosis \[[@B22]\]. Our data ([Figure 1](#F1){ref-type="fig"}E) do not concur with that study. The reasons why we did not observe a similar impact of Sbp1 on phagocytosis are unclear, but might reflect technical differences between the studies. The prior study used live bacteria, wherein phagocytosis *per se* can be confounded by intracellular killing by the host phagocyte. Thus, differences in the recovery of live cells from macrophages may represent a composite endpoint related to both internalization of bacteria and intracellular killing. On the other hand, we used nonviable (heat-inactivated) bacteria, which removes the influence of bacterial killing as a confounder but also eliminates active bacterial processes that might influence host cell engagement and internalization. Our studies also used different macrophage cell lines. The previous study used a mouse tumor cell line \[[@B23]\], while we used a differentiated human monocytic leukemia cell line \[[@B8]\]. Future studies are needed to clarify the basis of the differences between these two studies.

In summary, this study demonstrates that structural and/or biochemical differences among diverse GBS strains are reflected in a diverse capacity for macrophages to ingest them through non-opsonic phagocytosis. The exact mechanisms explaining these differences are not clear. The extent to which the findings from this study are relevant to the pathogenesis of human infection is also unclear.
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